Amicus Therapeutics, Inc. provided revenue guidance for the year 2023. For the year, the company anticipates double-digit Galafold revenue growth of 12% to 17% at constant exchange rates. Growth is expected to be driven by continued underlying demand from both switch and treatment-naïve patients, geographic expansion, continued diagnosis of new Fabry patients, and commercial execution across all major markets, including the U.S., EU, U.K., and Japan.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.6 USD | -2.21% |
|
+2.61% | -25.30% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.30% | 3.21B | |
+24.74% | 47.96B | |
-0.47% | 42.45B | |
+43.96% | 41.47B | |
+25.40% | 31.6B | |
+17.96% | 28.63B | |
-4.47% | 28.03B | |
+50.73% | 14.56B | |
+42.56% | 14.14B | |
+1.46% | 12.58B |
- Stock Market
- Equities
- FOLD Stock
- News Amicus Therapeutics, Inc.
- Amicus Therapeutics, Inc. Provides Revenue Guidance for the Year 2023